1.
Is there a place for nebulised magnesium sulphate in the management of asthma?
Lyons, J
Emergency nurse : the journal of the RCN Accident and Emergency Nursing Association. 2016;(7):28-33
Abstract
Intravenous magnesium sulphate (MgSO4) is an accepted part of the pharmacological management of patients with asthma. There is conflicting information, however, on whether its nebulised form is beneficial. This article describes a case study in which a patient was given intravenous MgSO4. It was suggested by a medical consultant that she could have been given nebulised MgSO4, so a literature review was undertaken to examine its efficacy. The results suggest there is no evidence to support the use of nebulised MgSO4 in the management of patients with asthma.
2.
Churg-Strauss syndrome associated with montelukast therapy.
Girszyn, N, Amiot, N, Lahaxe, L, Cuvelier, A, Courville, P, Marie, I
QJM : monthly journal of the Association of Physicians. 2008;(8):669-71
3.
Drug therapy in the management of acute asthma.
Carroll, W, Lenney, W
Archives of disease in childhood. Education and practice edition. 2007;(3):ep82-6
4.
Breath malodor in an asthmatic patient caused by side-effects of medication: a case report and review of the literature.
Murata, T, Fujiyama, Y, Yamaga, T, Miyazaki, H
Oral diseases. 2003;(5):273-6
Abstract
OBJECTIVE The purpose of this report is to document the presence of dimethyl sulfide in mouth air as the predominant volatile sulfur compound (VSC) in an asthmatic patient who was regularly taking suplatast tosilate. STUDY DESIGN The patient was a 33-year-old woman who complained of bad breath. She had been diagnosed as having asthma and was receiving periodical medical examinations once a month. VSC in her mouth air were measured with a gas chromatograph. Oral physiotherapy was also carried out to remove any oral malodor of which the source was intraoral. RESULTS With the improvement in oral hygiene and periodontal conditions, the level of VSC was reduced but dimethyl sulfide still remained as the predominant VSC. CONCLUSIONS Dimethyl sulfide metabolized from suplatast tosilate may be a potential cause of halitosis.
5.
Churg-Strauss syndrome in two patients receiving montelukast.
Guilpain, P, Viallard, JF, Lagarde, P, Cohen, P, Kambouchner, M, Pellegrin, JL, Guillevin, L
Rheumatology (Oxford, England). 2002;(5):535-9
Abstract
OBJECTIVE Churg-Strauss syndrome (CSS) has been described in association with the treatment of asthmatic patients with leukotriene receptor antagonist. The main mechanism proposed to explain this condition is the unmasking of CSS after the leukotriene receptor antagonist has allowed corticosteroid tapering. Other hypotheses might be proposed. METHODS We describe two patients who developed CSS after starting treatment with montelukast, a new antileukotriene drug. RESULTS Both patients presented with CSS after 4-5 months of treatment with montelukast. Neither patient received long-term systemic steroids for asthma, but both were on inhaled steroids. One patient had a myocardial involvement and experienced a stroke. Our two patients were treated with systemic steroids and cyclophosphamide. CONCLUSIONS CSS does not appear to relate to steroid tapering in our patients. The other hypotheses are a coincidence or a direct adverse effect of the antileukotriene. Long-term data on these drugs are lacking and leukotriene's role in vasculitis remains to be elucidated.
6.
[Churg-Strauss syndrome associated with montelukast therapy].
Sabadell, C, Jolis, R, CanalĂas, J
Medicina clinica. 2001;(4):159